GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SINTX Technologies Inc (NAS:SINT) » Definitions » 3-Year EBITDA Growth Rate

SINT (SINTX Technologies) 3-Year EBITDA Growth Rate : 88.60% (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is SINTX Technologies 3-Year EBITDA Growth Rate?

SINTX Technologies's EBITDA per Share for the three months ended in Dec. 2024 was $-1.08.

During the past 3 years, the average EBITDA Per Share Growth Rate was 88.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of SINTX Technologies was 88.60% per year. The lowest was 64.20% per year. And the median was 76.40% per year.


Competitive Comparison of SINTX Technologies's 3-Year EBITDA Growth Rate

For the Medical Devices subindustry, SINTX Technologies's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SINTX Technologies's 3-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SINTX Technologies's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where SINTX Technologies's 3-Year EBITDA Growth Rate falls into.


;
;

SINTX Technologies 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


SINTX Technologies  (NAS:SINT) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


SINTX Technologies 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of SINTX Technologies's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


SINTX Technologies Business Description

Traded in Other Exchanges
Address
1885 West 2100 South, Salt Lake City, UT, USA, 84119
SINTX Technologies Inc is an advanced ceramics company, focused on providing solutions in a variety of biomedical, technical, and antipathogenic applications. It has grown from focusing primarily on the research, development, and commercialization of medical devices manufactured with silicon nitride to becoming an advanced ceramics company engaged in diverse fields, including biomedical, technical, and antipathogenic applications. Its biomedical products are biocompatible, bioactive, antipathogenic, and to have superb bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans in the US, Europe, Brazil, and Taiwan.
Executives
David W. Truetzel director C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET, SALT LAKE CITY UT 84119
David Francis O'brien officer: Chief Operating Officer 1885 WEST 2100 SOUTH, SALT LAKE CITY UT 84119
Ty Lombardi officer: VP Finance C/O AMEDICA CORPORATION, 1885 W 2100 SOUTH, SALT LAKE CITY UT 84119
Eric A Stookey director 5677 AIRLINE ROAD, ARLINGTON TN 38002
Gordon Esplin officer: Vice President, Finance C/O AMEDICA CORPORATION, 1885 WEST 2100 SOUTH, SALT LAKE CITY UT 84119
Kevin Ontiveros officer: See Remarks C/O IMARX THERAPEUTICS INC, 1635 EAST 18TH STREET, TUCSON AZ 85719
Arthur Karl Kipke 10 percent owner C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119
Jay M Moyes director, officer: Chief Fnancial Officer
Vytas Rupinskas officer: SVP, Marketing C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Eric K. Olson director, officer: President and CEO C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119
James P. Abraham officer: SVP, Global Sales C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Christopher Whitfield officer: Chief Commercial Officer C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Max Link director 509 MADISON AVE 14TH FL, NEW YORK NY 10022
Kevin L Davis officer: Chief Operating Officer 9149 SOUTH MONROE PLAZA WAY, SUITE B, SANDY UT 84070
Jeffrey S. White director C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119